Merck & Co. Inc. (MRK) Stock Price Prediction
AI-generated price target with bull & bear cases · Re-evaluated every trading morning and evening
Our AI model’s current price target for MRK is $153.63 — 3.9% above the latest price of $147.86.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bull case for Merck is underpinned by the continued strong performance and expanding indications of Keytruda, particularly in earlier-stage cancers, and the successful uptake of new product launches such as WINREVAIR (up 75% in Q2 2026), WELIREG (up 67%), and CAPVAXIVE (up 40%), along with the recent FDA approval of LIPFENDRA. Merck's robust and growing pipeline, especially in oncology, holds significant commercial opportunities estimated at over $50 billion by the mid-2030s. Strategic collaborations, including the personalized cancer vaccine with Moderna, are expected to drive innovation and growth. The company's strong balance sheet and substantial free cash flow provide flexibility for strategic investments and sustained dividend payments, further supporting investor confidence and potential stock appreciation.
Bear Case
The primary concern in the bear case for Merck is the substantial reliance on Keytruda, which faces patent expiration in the coming years, notably around 2028, posing a significant risk to future revenues. The stock's currently high P/E ratio (e.g., 118.58) suggests that it may be overvalued, with some intrinsic value analyses indicating it is overvalued by 25%. Slower-than-anticipated growth from new product launches or disappointing results from its extensive pipeline could negatively impact the stock. Additionally, successful challenges to key patents, delays in regulatory approvals, or unfavorable macroeconomic conditions that lead to a market rotation away from defensive stocks could exert downward pressure. The high dividend payout ratio (268.80%) also raises questions about the sustainability of its dividend policy without consistent profit growth. A decline in sales of other key products, such as the 22% drop in Gardasil sales in Q1 2026, also presents a headwind.
Model-assessed risk level: Medium
Key Catalysts to Watch
Upcoming Phase 3 data readouts from its robust pipeline.
Successful launch and continued strong uptake of new products (e.g., WINREVAIR, WELIREG, CAPVAXIVE, LIPFENDRA).
Results from clinical trials for its personalized cancer vaccine in collaboration with Moderna.
Further strategic business development activities, including potential acquisitions and collaborations.
Q3 2026 earnings report, estimated for October 29, 2026.
Technical Backdrop
RSI-14
61.8
50-Day MA
$131.86
200-Day MA
$107.68
From 52-Wk High
-5.5%
Full momentum breakdown: Is MRK overbought or oversold?
Model Notes
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is recognized as one of the largest biomedical companies by revenue. The company focuses on developing, manufacturing, and selling prescription medicines, vaccines, biologic therapies, and animal health products. Key revenue drivers include cancer treatments like Keytruda and vaccines such as Gardasil. Merck reported strong financial results for Q1 and Q2 2026, driven by robust performance in oncology, animal health, and the successful launch of new products. The company has a diverse product portfolio, a strong pipeline, and is actively pursuing strategic collaborations to fuel future growth.
Merck (MRK) is currently in a rising trend channel over the medium to long term, indicating a positive trajectory for the company's stock price. Technical indicators largely suggest a bullish sentiment, with the stock trading above its 20-day, 50-day, and 200-day simple moving averages, which are typically considered 'Buy' signals. The Moving Average Convergence Divergence (MACD) indicator shows mixed signals across different analyses, while the Relative Strength Index (RSI) ranges from suggesting a 'Buy' to 'Neutral' condition. The positive volume balance further indicates increasing optimism among investors. However, some short-term moving averages suggest 'Sell' signals, and the stock's price is near its 52-week high, warranting careful monitoring.
Current Street Context
August 31, 2026The AI price target for Merck & Co. Inc. is $153.63. In the absence of specific recent analyst reports or upcoming earnings dates in the provided search results for August 2026, this target likely reflects a general positive outlook on the company's pharmaceutical portfolio and pipeline. Merck's strong market position, particularly with its oncology drug Keytruda, often contributes to favorable analyst sentiment. Key upcoming events would typically include future earnings announcements, clinical trial readouts, and potential new product launches or regulatory approvals. Macroeconomic factors impacting healthcare spending and drug pricing could also influence future estimates. It is important to remember that price targets are estimates and not guarantees, and actual market performance can vary.
Frequently Asked Questions
What is the price target for MRK?
How is this forecast generated?
How accurate are stock price predictions?
Will MRK stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews MRK’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on MRK
Merck & Co. Inc. Overview
Price, chart, analysis & financials
MRK: Overbought or Oversold?
Updated daily
MRK: Why Is It Moving?
Updated daily
MRK: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers